Inhibitory effects of butein on cancer metastasis and bioenergetic modulation

Journal of Agricultural and Food Chemistry

Volumn 62, Issue 37, 2014, Pages 9109-9117

  Liu, Shih Chia ^a   Chen, Chi ^b   Chung, Ching Hu ^b   Wang, Po Chuan ^a   Wu, Nan Lin ^a,b   Cheng, Jen Kun ^a,b   Lai, Yu Wei ^c   Sun, Hui Lung ^d   Peng, Chieh Yu ^e   Tang, Chih Hsin ^e,f   Wang, Shih Wei ^b  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d OHIO STATE UNIVERSITY   (United States)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

Author keywords

Bioenergetics; Butein; Metastasis

Indexed keywords

BIOCHEMISTRY; CELLS; ENZYME INHIBITION; MACHINERY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTICANCER EFFECTS; BIOENERGETICS; BUTEIN; HUMAN CANCER CELLS; MATRIX METALLOPROTEINASE 9 (MMP 9); METASTASIS; PROTEOLYTIC ACTIVITIES; UROKINASE PLASMINOGEN ACTIVATORS (UPA);

DISEASES;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BUTEIN; CHALCONE DERIVATIVE; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; UROKINASE;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; ENERGY METABOLISM; GLYCOLYSIS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OXIDATIVE PHOSPHORYLATION; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CHALCONES; ENERGY METABOLISM; GLYCOLYSIS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OXIDATIVE PHOSPHORYLATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84924227671     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf502370c     Document Type: Article

References (40)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin 2011, 61, 69-90.
2. Chaffer, C. L.; Weinberg, R. A. A perspective on cancer cell metastasis. Science 2011, 331, 1559-1564.
3. Deryugina, E. I.; Quigley, J. P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25, 9-34.
4. Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278, 16-27.
5. Dass, K.; Ahmad, A.; Azmi, A. S.; Sarkar, S. H.; Sarkar, F. H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev. 2008, 34, 122-136.
6. Sasaki, M.; Kashima, M.; Ito, T.; Watanabe, A.; Izumiyama, N.; Sano, M.; Kagaya, M.; Shioya, T.; Miura, M. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1β and TNF-α. Mediators Inflamm. 2000, 9, 155-160.
7. Cho, A.; Graves, J.; Reidy, M. A. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2527-2532.
8. St-Pierre, Y.; Couillard, J.; Van Themsche, C. Regulation of MMP- 9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin. Ther. Targets 2004, 8, 473-489.
9. Ulisse, S.; Baldini, E.; Sorrenti, S.; D'Armiento, M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 2009, 9, 32-71.
10. Harbeck, N.; Kates, R. E.; Gauger, K.; Willems, A.; Kiechle, M.; Magdolen, V.; Schmitt, M. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb. Haemostasis 2004, 91, 450-456.
11. Zheng, Q.; Tang, Z. Y.; Xue, Q.; Shi, D. R.; Song, H. Y.; Tang, H. B. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J. Cancer Res. Clin. Oncol. 2000, 126, 641-646.
12. Zhang, Y.; Guan, X. Y.; Dong, B.; Zhao, M.; Wu, J. H.; Tian, X. Y.; Hao, C. Y. Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinic pathological features. J. Cancer Res. Clin. Oncol. 2012, 138, 2035-2044.
13. Lee, H. C.; Wei, Y. H. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int. J. Biochem. Cell Biol. 2005, 37, 822-834.
14. Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13, 472-482.
15. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
16. Koukourakis, M. I.; Giatromanolaki, A.; Harris, A. L.; Sivridis, E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumorassociated stroma. Cancer Res. 2006, 66, 632-637.
17. Lardner, A. The effects of extracellular pH on immune function. J. Leukocyte Biol. 2001, 69, 522-530.
18. Pandey, M. K.; Sandur, S. K.; Sung, B.; Sethi, G.; Kunnumakkara, A. B.; Aggarwal, B. B. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-κB and NF-κB-regulated gene expression through direct inhibition of IκBα kinase β on cysteine 179 residue. J. Biol. Chem. 2007, 282, 17340-17350.
19. Chen, Y. N.; Huang, T. F.; Chang, C. H.; Hsu, C. C.; Lin, K. T.; Wang, S. W.; Peng, H. C.; Chung, C. H. Anti restenosis effect of butein in the neointima formation progression. J. Agric. Food Chem. 2012, 60, 6832-6838.
20. Cheng, Z. J.; Kuo, S. C.; Chan, S. C.; Ko, F. N.; Teng, C. M. Antioxidant properties of butein isolated from Dalbergia odorifera. Biochim. Biophys. Acta 1998, 1392, 291-299.
21. Lee, S. H.; Seo, G. S.; Sohn, D. H. Inhibition of lipopolysaccharide- induced expression of inducible nitric oxide synthase by butein in RAW 264.7 cells. Biochem. Biophys. Res. Commun. 2004, 323, 125-132.
22. Chung, C. H.; Chang, C. H.; Chen, S. S.; Wang, H. H.; Yen, J. Y.; Hsiao, C. J.; Wu, N. L.; Chen, Y. L.; Huang, T. F.; Wang, P. C.; Yeh, H. I.; Wang, S. W. Butein inhibits angiogenesis of human endothelial progenitor cells via the translation dependent signaling pathway. Evidence-Based Complement. Altern. Med.: eCAM 2013, 2013, No. 943187.
23. Chua, A. W.; Hay, H. S.; Rajendran, P.; Shanmugam, M. K.; Li, F.; Bist, P.; Koay, E. S.; Lim, L. H.; Kumar, A. P.; Sethi, G. Butein down regulates chemokine receptor CXCR4 expression and function through suppression of NF-κB activation in breast and pancreatic tumor cells. Biochem. Pharmacol. 2010, 80, 1553-1562.
24. Moon, D. O.; Kim, M. O.; Lee, J. D.; Choi, Y. H.; Kim, G. Y. Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett. 2009, 286, 172-179.
25. Ma, C. Y.; Ji, W. T.; Chueh, F. S.; Yang, J. S.; Chen, P. Y.; Yu, C. C.; Chung, J. G. Butein inhibits the migration and invasion of SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK, JNK, p38, and uPA signaling multiple pathways. J. Agric. Food Chem. 2011, 59, 9032-9038.
26. Kim, J.; Yu, W.; Kovalski, K.; Ossowski, L. Requirement for specific proteases in cancer cell intra vasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998, 94, 353-362.
27. Wang, S. W.; Wu, H. H.; Liu, S. C.; Wang, P. C.; Ou, W. C.; Chou, W. Y.; Shen, Y. S.; Tang, C. H. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One 2012, 7, e35101.
28. Mamane, Y.; Petroulakis, E.; LeBacquer, O.; Sonenberg, N. mTOR, translation initiation and cancer. Oncogene 2006, 25, 6416- 6422.
29. Yang, S. F.; Yang, W. E.; Kuo, W. H.; Chang, H. R.; Chu, S. C.; Hsieh, Y. S. Anti metastatic potentials of flavones on oral cancer cell via an inhibition of matrix-degrading proteases. Arch. Oral Biol. 2008, 53, 287-294.
30. Huang, H. Y.; Jiang, Z. F.; Li, Q. X.; Liu, J. Y.; Wang, T.; Zhang, R.; Zhao, J.; Xu, Y. M.; Bao, W.; Zhang, Y.; Jia, L. T.; Yang, A. G. Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator. Cancer Invest. 2010, 28, 689-697.
31. Kunigal, S.; Lakka, S. S.; Gondi, C. S.; Estes, N.; Rao, J. S. RNA imediated down regulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int. J. Cancer 2007, 121, 2307-2316.
32. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 2004, 18, 1926-1945.
33. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8, 179-183.
34. Wang, C. H.; Cao, G. F.; Jiang, Q.; Yao, J. TNF-α promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt/mTORC1 signaling. Biochem. Biophys. Res. Commun. 2012, 425, 33-38.
35. Busch, S.; Renaud, S. J.; Schleussner, E.; Graham, C. H.; Markert, U. R. mTOR mediates human trophoblast invasion through regulation of matrix-remodeling enzymes and is associated with serine phosphorylation of STAT3. Exp. Cell Res. 2009, 315, 1724-1733.
36. Murooka, T. T.; Rahbar, R.; Platanias, L. C.; Fish, E. N. CCL5- mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 2008, 111, 4892-4901.
37. Wu, M.; Neilson, A.; Swift, A. L.; Moran, R.; Tamagnine, J.; Parslow, D.; Armistead, S.; Lemire, K.; Orrell, J.; Teich, J.; Chomicz, S.; Ferrick, D. A. Multi parameter metabolic analysis reveals a close link between attenuated mitochondrial bio energetic function and enhanced glycolysis dependency in human tumor cells. Am. J. Physiol. Cell Physiol. 2007, 292, C125-C136.
38. Sottnik, J. L.; Lori, J. C.; Rose, B. J.; Thamm, D. H. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin. Exp. Metastasis 2011, 28, 865-875.
39. Dennis, P. B.; Jaeschke, A.; Saitoh, M.; Fowler, B.; Kozma, S. C.; Thomas, G. Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294, 1102-1105.
40. Kong, D.; Li, Y.; Wang, Z.; Banerjee, S.; Sarkar, F. H. Inhibition of angiogenesis and invasion by 3, 3′-diindolylmethane is mediated by the nuclear factor-κB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007, 67, 3310-3319.